Taken together, our findings indicate that augmented HER2 signaling contributes to the upregulation of YTHDF1 expression, further implying a critical role for YTHDF1 in sustaining the activation of downstream signaling pathways associated with HER2‐positive cancers.[31] Furthermore, YTHDF1 upregulation is implicated in immune evasion mechanisms observed in HER2‐positive GC.[32]. Here, ERBB2 is linked to cancer.